Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Iams Wealth Management LLC

Iams Wealth Management LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 27.0% during the 4th quarter, Holdings Channel reports. The fund owned 3,222 shares of the medical research company’s stock after acquiring an additional 685 shares during the quarter. Iams Wealth Management LLC’s holdings in Amgen were worth $840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new stake in shares of Amgen during the third quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new position in Amgen during the 3rd quarter valued at $29,000. Matrix Trust Co acquired a new position in shares of Amgen during the 3rd quarter valued at $36,000. Livelsberger Financial Advisory bought a new stake in shares of Amgen in the 3rd quarter worth $56,000. Finally, Icon Wealth Advisors LLC lifted its holdings in shares of Amgen by 3,955.0% in the third quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock valued at $56,000 after buying an additional 169,748 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.4 %

Shares of NASDAQ AMGN opened at $281.28 on Wednesday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm’s 50-day simple moving average is $271.48 and its 200 day simple moving average is $305.15. The company has a market cap of $151.20 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the company posted $4.96 EPS. The company’s revenue was up 23.2% compared to the same quarter last year. On average, research analysts expect that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.38%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 115.24%.

Analysts Set New Price Targets

AMGN has been the topic of several research reports. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft decreased their price target on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. TD Cowen boosted their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. UBS Group decreased their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Finally, Truist Financial reduced their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.